-

WEIS MARKETS INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Weis Markets, Inc. (“Weis Markets” or the “Company”) (NYSE:WMK). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On February 26, 2026, Weis Markets filed a Form 8-K disclosing that certain previously issued financial statements, including audited financial statements for fiscal years 2022 through 2024 and interim financial statements in 2025, will be restated due to inaccurately recorded and overstated inventory. The Company also announced that it will delay the filing of its 2025 Annual Report on Form 10-K while it completes the review and restatement process.

On this news, the price of Weis Market shares declined by $5.12 per share, or approximately 7.16%, from $71.51 per share on February 25, 2026 to close at $66.39 on February 26, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Weis Markets securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Kirby McInerney LLP

NYSE:WMK

Release Versions

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

More News From Kirby McInerney LLP

INVESTOR ALERT: Securities Class Action Filed Against Coty Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Coty Inc. (“Coty” or the “Company”) (NYSE:COTY) securities during the period of November 5, 2025 through February 4, 2026, inclusive (“the Class Period”). If you suffered a loss on your Coty investments, you have until May 22, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this dead...

TRUBRIDGE, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against TruBridge, Inc. (“TruBridge” or the “Company”) (NASDAQ:TBRG). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 16, 2026, TruBridge disclosed that it would be unable to timely file its 2025 Annual Report b...

INVESTOR ALERT: Securities Class Action Filed Against Atara Biotherapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) securities during the period of May 20, 2024 through January 9, 2026, inclusive (“the Class Period”). If you suffered a loss on your Atara investments, you have until May 22, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitte...
Back to Newsroom